No price history available.
Key financial summary
Financials in NZD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | NZDm | 195 | 192 | 209 | 234 | 201 | 192 | N/A | N/A |
| Operating profit | NZDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | NZDm | -10 | 9 | 13 | 11 | -77 | -105 | N/A | N/A |
| EPS reported | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | NZDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | NZDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | NZDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | NZD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in NZD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Comvita Limited, along with its associated entities, specializes in the global production and distribution of natural health products. The company boasts a significant international presence, operating across diverse markets in Australasia, Asia (including China), North America, Europe, the Middle East, and Africa. Its extensive product portfolio features flagship items such as Manuka honey, propolis, and olive leaf extract. Additionally, it offers a wide array of medihoney, skincare, gourmet honey, elixirs, lozenges, and cider vinegar formulations, as well as dedicated solutions for oral and children's health. Comvita's range is meticulously designed to address diverse wellness needs, including supporting digestive health, soothing eczema-prone skin, boosting energy levels, promoting cardiovascular well-being, and fortifying immune support. The company also provides essential solutions for summer and travel requirements. Beyond product development, Comvita maintains a vertically integrated operational model, encompassing the ownership and management of apiaries (beekeeping operations), property assets, and valuable intellectual property. Established in 1974, Comvita Limited is headquartered in Te Puke, New Zealand.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Comvita Limited, along with its associated entities, specializes in the global production and distribution of natural health products. The company boasts a significant international presence, operating across diverse markets in Australasia, Asia (including China), North America, Europe, the Middle East, and Africa. Its extensive product portfolio features flagship items such as Manuka honey, propolis, and olive leaf extract. Additionally, it offers a wide array of medihoney, skincare, gourmet honey, elixirs, lozenges, and cider vinegar formulations, as well as dedicated solutions for oral and children's health. Comvita's range is meticulously designed to address diverse wellness needs, including supporting digestive health, soothing eczema-prone skin, boosting energy levels, promoting cardiovascular well-being, and fortifying immune support. The company also provides essential solutions for summer and travel requirements. Beyond product development, Comvita maintains a vertically integrated operational model, encompassing the ownership and management of apiaries (beekeeping operations), property assets, and valuable intellectual property. Established in 1974, Comvita Limited is headquartered in Te Puke, New Zealand.
